Kaplan-Meier plot of time to first use of a wheelchair by treatment... | Download Scientific Diagram
:max_bytes(150000):strip_icc()/types-of-multiple-sclerosis-5200710_final-80ec48e459554962a559890ad290a980.jpg "Types of Multiple Sclerosis (MS): Progression, Outlook")
Types of Multiple Sclerosis (MS): Progression, Outlook
10 Essential Facts About Primary-Progressive MS
#ECTRIMS2019 - Early Ocrevus Use in PPMS Slows Disability, Including Risk of Wheelchair Reliance
The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text
Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021 | Neurology and Therapy
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability - Jerry S Wolinsky, Natalie J Engmann, Jinglan Pei, Ashish Pradhan, Clyde Markowitz, Edward J Fox,
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library
DMTs may reduce risk for becoming wheelchair dependent in patients with PPMS
Part I: Understanding Progression in MS | MSAA
Time to, and age at, EDSS 4.0, 6.0 and 8.0 based upon Kaplan-Meier... | Download Table
PPMS: Prognosis and Life Expectancy | MyMSTeam
Primary progressive MS: Symptoms, diagnosis, and treatment
Primary progressive MS: Symptoms, diagnosis, and treatment
MS prognosis and life expectancy
My Taking My Life Back Bucket List | MS And Me Media
JCM | Free Full-Text | Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
Primary-Progressive MS: 6 Top Technology Recommendations
:max_bytes(150000):strip_icc()/GettyImages-946607840-04786118927148b094e830894c0caae9.jpg "Progressive-Relapsing MS: Symptoms, Causes, Treatment")
Progressive-Relapsing MS: Symptoms, Causes, Treatment
The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry | BMC Neurology | Full Text
Multiple Sclerosis Research: Disease course of PPMS
The Best Power Wheelchair for Multiple Sclerosis by Redman Power Chair
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials - eBioMedicine
Multiple Sclerosis Patient Stories - Mitch, MS Advocate - Atara Biotherapeutics
Ocrevus May Delay by 7 Years PPMS Patients' Need for Wheelchair
Blood Neurofilament Light in Progressive Multiple Sclerosis | Neurology
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry - Butzkueven - 2022 - European Journal of Neurology - Wiley Online Library
